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Abstract Phospholipase D1 (PLD1) is known to be activated
by ADP-ribosylation factor 1 (ARF1). We report here that
ARF1 co-immunoprecipitates with PLD1 and that the ARF1-
dependent PLD activation is induced by the direct interaction
between ARF1 and PLD1. We found that RalA, another member
of the small GTP-binding proteins, synergistically enhances the
ARF1-dependent PLD activity with an EC50 of about 30 nM.
Using in vitro binding assay, we show that ARF1 and RalA
directly interact with different sites of PLD1. The results suggest
that the independent interactions of RalA and ARF1 with PLD1
are responsible for the synergistic activation.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Phospholipase D (PLD) catalyzes the hydrolysis of phos-
phatidylcholine (PC) to produce choline and phosphatidic
acid (PA). PA appears to be a second messenger in multiple
signaling events, and its production can be regulated by a
variety of extracellular agonists including hormones and
growth factors [1,2].
It has been suggested that agonist-dependent PLD activa-
tion is mediated by protein kinase C (PKC), calcium ion, low
molecular weight GTP-binding proteins (small G proteins) of
the Ras superfamily, and protein-tyrosine kinases [3]. Several
studies have demonstrated the involvement of the ADP-ribo-
sylation factor, a member of the small G protein family, in
PLD activation [4,5]. ARF was reported to synergistically
stimulate PLD activity in concert with small G proteins of
the Rho family including RhoA, Cdc42, and Rac1 [6]. In
addition to the small G proteins, PKC-K has been shown to
stimulate PLD activity, and PLD activation by PKC-K occurs
synergistically with ARF and RhoA [7,8]. The molecular na-
ture of ARF-, RhoA-, and PKC-dependent PLD has been
recently elucidated and designated PLD1 [9,10].
RalA, another member of the small G protein family, was
reported to play a role in v-Src, a non-receptor protein-tyro-
sine kinase, induced PLD activation [11]. RalA was reported
to interact with the v-Src-dependent PLD, however, RalA did
not directly stimulate PLD activity [11]. Thus, the role of
RalA in v-Src-induced PLD activation is still ambiguous.
Previously, we demonstrated the stimulation of PLD activ-
ity by direct interaction of PLD1 with PKC-K in a phorbol
12-myristate 13-acetate (PMA)-dependent manner [12]. In
contrast, it is still unknown whether the small G protein-de-
pendent PLD activation is mediated by direct interaction with
PLD1. In the present study, we show evidence for the ¢rst
time that ARF1 and RalA directly interact with di¡erent sites
on PLD1, that RalA synergistically stimulates PLD1 activity
in concert with ARF, and we suggest a role for PLD1 as a
point of convergence of diverse PLD-activating signals.
2. Materials and methods
2.1. Materials
Dioleoyl-phosphatidylethanolamine (dioleoyl-PE), dipalmitoyl-
phosphatidylcholine (dipalmitoyl-PC), and phosphatidylinositol 4,5-
bisphosphate (PIP2) were purchased from Sigma. The enhanced chem-
iluminescence kit and dipalmitoylphosphatidyl-[methyl-3H]choline
were purchased from Amersham International (Buckinghamshire,
UK). GTPQS, GDPLS, and thrombin were obtained from Boehringer
Mannheim (Mannheim, Germany). SP-Sepharose and glutathione-
Sepharose were from Pharmacia Biotech Inc. (Uppsala, Sweden).
Anti-RalA antibody was obtained from Transduction Lab (Lexing-
ton, KY, USA). Horseradish peroxidase-conjugated goat anti-rabbit
or anti-mouse IgG were from Upstate Biotechnology Inc. (Lake
Placid, NY, USA). Pansorbin cells and L-octyl glucopyranoside
were obtained from Calbiochem (San Diego, CA, USA).
2.2. Preparation of GST-RalA fusion protein and ARF1
The cDNA for RalA was isolated by polymerase chain reaction
(PCR) and inserted into the appropriate site of the PGEX-4T vector
(Pharmacia Biotechnology). The glutathione-S-transferase-RalA
(GST-RalA) fusion protein was induced in Escherichia coli by adding
100 WM isopropyl-1-thio-L-D-galactopyranoside followed by growth at
37‡C for 5 h. The GST-RalA fusion protein was puri¢ed using glu-
tathione-Sepharose, and RalA was released from the immobilized
GST-RalA fusion protein with thrombin essentially as described
[13]. Thrombin was removed by incubation with benzamidine-Sephar-
ose 6B beads (Pharmacia). Myristoylated recombinant ARF1 was ex-
pressed in Escherichia coli and puri¢ed as described [14]. All recombi-
nant proteins were puri¢ed to greater than 95% homogeneity as
judged by Coomassie Blue staining of SDS gels.
2.3. Puri¢cation of phospholipase D1 from bovine brain
PLD1 was puri¢ed from the membrane fraction of bovine brain
employing the anti-PLD1 antibody coupled to protein A-Sepharose
resin according to a slightly modi¢ed procedure reported previously
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[12]. In brief, PLD1 was partially puri¢ed from one bovine brain by
Sephadex G-50 and SP-Sepharose column chromatography as de-
scribed [15], further puri¢ed to homogeneity from this partially puri-
¢ed PLD1 fraction with the help of anti-PLD1 antibody coupled to
protein A-Sepharose, and eluted by treatment with bu¡er A contain-
ing 0.4 M NaCl, 1% L-octyl glucopyranoside, and 400 WM peptide
(TKLVPMEVWT) as described [12]. The ¢nal PLD1 preparation was
homogeneous and contained about 4 Wg of PLD1 as determined by
sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and Coomassie staining (data not shown).
2.4. Phospholipase D assay
PLD activity was measured by choline release from phosphatidyl-
choline as essentially described [5] with a slight modi¢cation. In brief,
aliquots of the puri¢ed PLD1 preparation were added to a standard
assay mixture containing 125 Wl of bu¡er B (50 mM Tris-HCl, pH 7.3,
3 mM MgCl2, 2 mM CaCl2, 3 mM EGTA, 80 mM KCl, and 1 mM
dithiothreitol) and 25 Wl of phospholipid vesicles composed of dioleo-
yl-PE, PIP2, and dipalmitoyl-PC in a molar ratio of 16:1.4:1 and
dipalmitoyl-[methyl-3H]choline (total 200 000 cpm/assay). Final con-
centration of PC was 3.3 WM. In some experiments, ARF1, RalA, and
guanine nucleotides were added to the reaction mixture to activate
PLD1.
2.5. Coimmunoprecipitation of ARF1 with PLD1
Puri¢ed PLD1 (0.1 Wg) was precipitated by immobilized anti-PLD1
antibody (1 Wg of a⁄nity-puri¢ed antibody/30 Wl of Pansorbin cells).
The immune complexes were incubated with 0.5 WM ARF1 and gua-
nine nucleotides in 150 Wl bu¡er B containing 0.5% L-octyl glucopyr-
anoside at 37‡C for 15 min. The resulting immune complexes were
washed twice with bu¡er B containing 0.5% L-octyl glucopyranoside,
further washed twice with bu¡er B, and resuspended in 50 Wl of bu¡er
B. The resuspended immune complexes were analyzed by SDS-PAGE
in an 8^16% gradient polyacrylamide gel and transferred onto a nitro-
cellulose ¢lter. The upper and lower parts of the nitrocellulose ¢lter
were probed with anti-PLD1 or anti-ARF1 antibody, respectively.
2.6. Binding of ARF1 and PLD1 to phospholipid vesicles
Mixed phospholipid vesicles composed of 53 WM PE, 3.3 WM PC,
and various concentrations of PIP2 were incubated with 10 ng PLD1,
0.5 WM ARF1, 10 WM GTPQS, and 150 Wg bovine serum albumin
(BSA) in 150 Wl bu¡er B. After incubation at 37‡C for 15 min, the
reaction mixtures were centrifuged at 300 000Ug for 20 min in a TL-
100 ultracentrifuge (Beckman). By inclusion of phosphatidyl-
[3H]inositol 4,5-bisphosphate or dipalmitoylphosphatidyl-[methyl-
3H]choline into the phospholipid vesicles, the recovery of precipitated
phospholipids was estimated to be above 95% and the recovery was
not a¡ected by the various concentrations of PIP2 and PLD1 (data
not shown). The pellets obtained after ultracentrifugation containing
phospholipid vesicles were resuspended and subjected to 8^16% SDS-
PAGE and immunoprobing using anti-PLD1 or anti-ARF antibodies.
2.7. Binding of PLD1 to immobilized GST-RalA fusion protein
Immobilized GST-RalA fusion protein was pre-incubated with
GTPQS or GDPLS according to the following procedure: the immo-
bilized protein was incubated with of 50 WM GTPQS or GDPLS in
bu¡er C (20 mM HEPES-NaOH pH 7.5, 10 mM EDTA, 5 mM
MgCl2, and 1 mM DTT) and washed twice with bu¡er B. Aliquots
of PLD1 (0.1 Wg) and 500 Wg BSA were incubated with the nucleotide-
preloaded immobilized proteins (10 Wg) in 500 Wl of bu¡er B contain-
ing 0.5% L-octyl glucopyranoside at 4‡C for 1 h. The immobilized
proteins were then washed twice with bu¡er B containing 0.5% L-octyl
glucopyranoside, resuspended in 50 Wl of 1U electrophoresis sample
bu¡er, and analyzed by SDS-PAGE and immunoprobing using the
anti-PLD1 antibody.
2.8. Western blotting
After electrophoresis, proteins were transferred to nitrocellulose by
electroblotting. After transfer, the nitrocellulose was blocked with
TTBS bu¡er (50 mM Tris-HCl, pH 7.4, 0.05% Tween 20, 150 mM
NaCl) containing 5% skimmed milk. Subsequently, the blots were
incubated with the ¢rst antibody (anti-PLD1 or anti-ARF1 in
TTBS containing 5% skimmed milk) for 2 h. The nitrocellulose mem-
branes were washed 4 times for 10 min with TTBS before incubation
with horseradish peroxidase conjugated anti-rabbit IgG for 1 h. Vis-
ualization of immune complexes was performed by a horseradish per-
oxidase-dependent chemiluminescence (ECL) kit.
3. Results
3.1. Association of ARF1 with PLD1
To ¢nd out whether ARF can directly bind to PLD1, PLD1
was immunoprecipitated with anti-PLD1 antibody, and the
immune complexes were incubated with ARF1 and guanine
nucleotides in the standard assay mixture. 0.5% L-octyl glu-
copyranoside was added to the reaction mixtures to prevent
non-speci¢c interaction between the immune complexes and
ARF1. The resultant immune complexes were resuspended
and added into an assay mixture that measured PLD activity
without or with additional inclusion of GTPQS. As shown in
Fig. 1A, the ARF1- and GTPQS-pre-treated immune complex
showed PLD activities which were not a¡ected by additional
inclusion of 10 WM GTPQS, suggesting the presence of GTPQS-
bound ARF1 in the immune complex. By probing Western
blots of the immune complexes with anti-ARF1 antibody, we
found that ARF1 indeed binds to PLD1 in the presence of
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Fig. 1. Association of ARF1 with PLD1. A: PLD1 (0.1 Wg)-coupled
immune complexes were incubated with 0.5 WM ARF1 as described
in Section 2. As a negative control, anti-PLD1 antibody (1 Wg)
coupled to Pansorbin cells (30 Wl) was also incubated with 0.5 WM
ARF1. 10 WM GTPQS (Q) or GDPLS (L) were included in the reac-
tion mixtures as indicated. To measure PLD activity, aliquots (10
Wl) of the resuspended immune complexes were added into the
standard assay mixtures with (+) or without (3) additional inclu-
sion of 10 WM GTPQS. The data shown are the means þ S.D. of
three independent experiments. B: Aliquots (40 Wl) of the resus-
pended immune complexes were subject to immunoblot analysis
with antibodies against PLD1 and ARF1 and visualized by ECL ex-
posure for 5 min. ARF1 (T) was subjected to immunoblot analysis
without prior immunoprecipitation and represent 10% (150 ng) of
the ARF1 used for the immunoprecipitation. The data are represen-
tative of three separate experiments.
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GTPQS but not GDPLS (Fig. 1B). These results suggest that
ARF1 interacts with PLD1 with high a⁄nity in the presence
of GTPQS, thus activating PLD activity.
3.2. Association of PLD1 and ARF1 with PIP2ÿcontaining
phospholipid vesicles
Recent reports implicated PIP2 in ARF-dependent PLD
activation as a cofactor and in guanine nucleotide exchange
of ARF1 through interaction with ARF1 [16^18]. Moreover,
interaction between PIP2 and partially puri¢ed rat brain PLD
has also been demonstrated [19]. Thus, it seemed promising to
examine the e¡ect of interactions between PLD1, ARF1, and
PIP2 on PLD activity. To ¢nd out whether PLD1 and ARF1
interact with PIP2, we added PLD1, ARF1, and PIP2-contain-
ing mixed phospholipid vesicles into reaction mixtures to
measure the amounts of PLD1 and ARF1 that would asso-
ciate with PIP2-containing phospholipid vesicles as described
in Section 2. As seen in Fig. 2A, PLD1 maximally binds to the
mixed phospholipid vesicles in the presence of 5 WM PIP2. We
found that PLD1 does not bind to phospholipid vesicles con-
taining PI instead of PIP2 (data not shown). The interaction
between PLD1 and the PIP2-containing phospholipid vesicles
was decreased by incubation with the pleckstrin-homology
domain of phospholipase C-N1 fused to GST (Fig. 2B), sug-
gesting that PLD1 binds to phospholipid vesicles through in-
teraction with PIP2. In support of our current observations,
Yokozeki et al. [19] have shown that pleckstrin homology
domain of L-adrenergic receptor kinase fused to GST inhibits
the interaction of rat brain PLD and PIP2. The amount of
ARF1 associated with phospholipid vesicles was augmented
by increased concentrations of PLD1 (Fig. 2C). Compared to
the level of ARF1 seen in Fig. 1B, the levels of ARF1 are very
low, thus prolonged exposure (30 min) for an ECL is re-
quired. The amount of ARF1 associated with about 0.18
pmol (1.2 nM) PLD1 is estimated to be more than 0.13
pmol (2.5 ng) but less than 0.26 pmol (5 ng), suggesting
that ARF1 may interact with PLD1 in an approximate ratio
of 1:1. Taken together, these results provide evidence for di-
rect interaction between PLD1 and ARF1.
3.3. E¡ects of RalA on basal and ARF1-dependent PLD
activities of PLD1
To determine the e¡ect of RalA on the enzymatic activity of
PLD1, we measured the basal and the ARF-dependent activ-
ities of PLD1 in the presence of GDPLS or GTPQS-preloaded
RalA. As can be seen in Fig. 3, GTPQS-preloaded RalA had a
small e¡ect on the basal activity of PLD1, whereas it in-
creased the ARF1-dependent PLD activity approximately
2.5-fold with an EC50 of 30 nM. In our study, we found
that preloading with GTPQS is critical for the RalA-induced
PLD activation (data not shown). Based on these results we
suggest that RalA is a separate PLD1-activating factor which
synergistically can stimulate PLD1 activity in concert with
ARF.
3.4. Independent association of ARF1 and RalA with PLD1
The synergistic PLD1 activation by ARF1 and RalA sug-
gested that PLD1 activity may be independently regulated by
the two separate signals. Thus, we examined whether the syn-
ergistic activation of PLD1 is mediated by direct interaction
between PLD1, RalA, and ARF1. As shown in Fig. 4A,
PLD1 speci¢cally bound not to immobilized GST but to the
immobilized GST-RalA fusion protein. PLD1 bound to the
immobilized GST-RalA fusion protein in a GTPQS-dependent
manner. Next, we examined whether PLD1 interacts with
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Fig. 3. E¡ects of RalA on basal and ARF1-dependent activity of
PLD1. The indicated concentrations of RalA were preincubated
with 50 WM GTPQS in bu¡er C in a ¢nal volume of 30 Wl at room
temperature for 30 min. The preincubated mixtures were added to
standard assay mixtures containing 0.5 WM ARF1 (closed circle)
and without ARF1 (open circle). The reaction was started by addi-
tion of aliquots (1 ng) of puri¢ed PLD1 to the assay mixtures and
incubated at 37‡C for 15 min. PLD activity was determined by
measuring the formation of [3H]choline as described in Section 2.
Data are the means þ S.D. of three independent experiments.
Fig. 2. Association of PLD1 and ARF1 with PIP2-containing phos-
pholipid vesicles. A: Aliquots (10 ng) of puri¢ed PLD1 were added
into standard assay mixtures containing phospholipid vesicles con-
taining the indicated concentrations of PIP2 as described in Section
2. B: Aliquots (10 ng) of PLD1 were reconstituted with phospho-
lipid vesicles containing 5 WM PIP2 and the indicated concentrations
of the pleckstrin-homology domain of PLC-N1 fused to GST. C: 0.5
WM ARF1 and 10 WM GTPQS were added to assay mixtures con-
taining the indicated concentrations of PLD1. The resultant pellets
of phospholipid vesicles, 10 ng PLD1 (C), and the indicated
amounts of ARF1 were analyzed by 8% SDS-PAGE, and probed
with anti-PLD1 or anti-ARF1 antibodies. PLD1 and ARF1 were
visualized by ECL exposure for 5 and 30 min, respectively. The
data are representative of three separate experiments.
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ARF1 and RalA through di¡erent binding sites. PLD1 was
pre-bound to the immobilized GST-RalA fusion protein, and
the resultant complexes were then further incubated with
ARF1 protein. As seen in Fig. 4B, ARF1 bound to the
PLD1-pre-bound GST-RalA fusion protein in a dose-depend-
ent manner but not to the GST-RalA fusion protein alone.
These results suggest that the synergistic activation of PLD1 is
mediated by the simultaneous interaction of RalA and ARF1
with di¡erent sites on PLD1.
4. Discussion
Several signaling molecules, PKC-K, protein tyrosine kin-
ases, and small G proteins including ARF and RhoA have
been implicated in the regulation of PLD activity [20]. How-
ever, the mechanism of PLD activation by the PLD-activating
factors is still unknown. In this study, we show evidence for
the ¢rst time that ARF1 and RalA directly interact with
PLD1 and that RalA synergistically stimulates ARF1-depend-
ent PLD activity.
We show that GTP-bound ARF1 interacts with PLD1 with
higher a⁄nity than GDP-bound ARF1 (Fig. 1). Recent evi-
dence suggested that PLD activation requires GTP-dependent
translocation of ARF1 from the cytosol to the membrane
[20,21]. Based on these observations, it is plausible that the
GTP-dependent translocation of ARF1 to the membrane may
give a function to the interaction between PLD1 and ARF1.
It has been reported that ARF1 requires PIP2 as a cofactor
for PLD activation [5,9]. PIP2 has been known to stimulate
the guanine nucleotide exchange activity of ARF1 [17]. In
addition, Randazzo [18] suggested that ARF1 binds to PIP2
and that PIP2 binding to ARF1 may direct the interaction
between ARF1 and ARF-interacting proteins, including the
ARF-GTPase-activating protein and PLD. In this study, we
show that PLD1 directly interacts with PIP2-containing phos-
pholipid vesicles, whereas the binding of ARF1 to the phos-
pholipid vesicles requires the presence of PLD1 (Fig. 2). These
results support the conclusion that ARF1-induced PLD acti-
vation may be mediated by direct association between PLD1
and ARF1.
We and other research groups demonstrated that PKC,
RhoA, and ARF are involved in PLD activation by growth
factors such as platelet-derived growth factor and epidermal
growth factor [22^25]. However, Jiang et al. [11] have impli-
cated RalA in v-Src, a non-receptor tyrosine kinase, induced
PLD activation via Ras-induced activation of Ral-GDS. In
our study, we found that RalA synergistically stimulates
ARF-induced PLD activity of PLD1. In keeping with our
observations, Luo et al. [26] demonstrated the direct interac-
tion of RalA with PLD1. Taken together, these results suggest
that PLD1 is regulated by di¡erent activating signals includ-
ing receptor- and non-receptor-tyrosine kinases through ARF,
RhoA, PKC, and RalA.
In order to elucidate the mechanism of the synergistic acti-
vation of PLD1, we asked whether the PLD activation is
mediated by the direct interaction of the PLD-activating
factors with PLD1. We previously demonstrated the
stimulation of PLD1 activity by direct interaction with
PKC-K in a PMA-dependent manner [12], suggesting that
PLD1 activity may be regulated by the direct interaction
with PLD1-activating factors. In this report, we show how
the synergistic activation by ARF1 and RalA is derived
from direct interaction with PLD1, suggesting an independent
interaction of ARF1 and RalA with di¡erent sites on PLD1.
Previous reports by several research groups [10,27] indicating
possible interactions of PLD1 with ARF1 or RalA are con-
sistent with our results. We therefore propose that PLD1
plays a key role in PLD activation by receiving di¡erent acti-
vating signals including receptor- or non-receptor-tyrosine
kinase activities.
In summary, our data show that RalA synergistically stim-
ulates the ARF-dependent PLD activity of PLD1 and that the
synergistic activation of PLD1 is based on the independent
interactions of PLD1 with PLD-activating factors. It will be
of great interest to characterize the sites of interaction be-
tween PLD1 and the PLD1-activating factors in their inde-
pendent association with the enzyme.
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Fig. 4. Independent interaction of RalA and ARF1 with PLD1. A:
Immobilized GST-RalA fusion protein was pre-incubated with
GTPQS (Q) or GDPLS (L) as described in Section 2. Aliquots (0.1
Wg) of puri¢ed PLD1 were incubated with the guanine nucleotide-
preloaded immobilized proteins. The resulting beads and 40 ng
PLD1 (T) were analyzed by 8% SDS-PAGE, and Western blots
probed with anti-PLD1 antibody. B: The PLD1-pre-bound immobi-
lized GST-RalA fusion protein was incubated with the indicated
concentrations of ARF1 under standard assay conditions containing
0.5% L-octyl glucopyranoside. The beads were washed twice with
bu¡er B containing 0.5% L-octyl glucopyranoside and subjected to
8^16% SDS-PAGE. The resolved proteins were transferred onto a
nitrocellulose membrane and stained with 2% Ponceau S to visualize
the GST-RalA fusion protein. The upper and lower parts of the
transfer ¢lter were probed with anti-PLD1 and ARF antibody, and
visualized by ECL exposure for 5 and 30 min, respectively.
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